A LloydsPharmacy Healthcare Centre based in Scunthorpe is the first pharmacy to provide an Omalizumab service through a partnership with Northern Lincolnshire and Goole NHS Foundation Trust (NLaG). The first clinic providing the service through a nurse-delivered sub cutaneous injection took place this month at the LloydsPharmacy branch in Marsden Drive.
Omalizumab, marketed under the trade name Xolair, is a medication designed to reduce sensitivity to allergens. The medication is used to try to control severe allergic asthma which does not respond to high doses of corticosteroids and for Chronic Spontaneous Urticaria.
Celesio UK (parent company of LloydsPharmacy) announced the launch of its Healthcare Centres late in 2017. The transformational new service supports hospitals to deliver treatments in the community instead of an acute hospital setting, thus creating efficiencies for the Trust and potential improvements to patient outcomes. Current services delivered under the Healthcare Centres concept include work with the Greater Manchester Cancer Vanguard to spot signs of cancer earlier and a pharmacist-delivered osteoporosis injection service (Denosumab) in the West Midlands.
Andy Burton, director of community services at Celesio UK, says: “We have worked with North Lincolnshire and Goole NHS Foundation Trust for many years and we run an outpatient service from our community pharmacy in Goole which serves the Goole and District Hospital and have outpatient hospital pharmacy dispensaries at the Scunthorpe General and Diana, Princess of Wales hospitals. This has been a good basis on which to build our relationship and evolve new services that deliver efficiencies for the Trust. In 2015 we developed a ‘dispense and deliver’ service for rheumatoid arthritis which allowed patients to have their medication delivered directly to their home or a local LloydsPharmacy community store so they did not have to visit hospital to receive their specialised medicines. More recent innovations have included a discharge dispensing pathway which allows more rapid discharge for patients and an electronic prescribing system for oncology into the outpatient setting.
“Our new immunology service was co-designed with referring clinical teams and consultants and allows patients to have their specialist medicines administered by a trained LloydsPharmacy Clinical Homecare (LPCH) nurse in a pharmacy clinic setting. Patients that are deemed appropriate by their consultant can now opt to receive this injection in their local community which can be more convenient as well as saving them time and money.”
Previously, patients requiring the treatment would have had to visit Scunthorpe General Hospital every four weeks to receive injections.
Paul Fieldhouse, chief pharmacist and clinical lead for medicines optimisation at Northern Lincolnshire and Goole NHS Foundation Trust, said: “This new innovative service is a great example of collaboration between hospitals and community pharmacy to deliver a new service to meet patients’ requirements. It’s great to see Scunthorpe General Hospital at the forefront of developing new services in the NHS.”
Paulash Haider, lead pharmacist medication safety and procurement at Northern Lincolnshire and Goole NHS Foundation Trust, said: “This arrangement is a real positive for the Trust. It’s an integrated approach to working which allows more specialist areas to be focused on by our staff in the hospital.
“There are patients who we treat who require greater clinical contact time and, as a result of this cooperative engagement programme, we’ll be able to offer this.”